Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (May 2017)
21 slides from Cynata Therapeutics's investor presentation, May 29, 2017
Slide 1: A Next Generation Stem Cell Company
For personal use only A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited May 2017
Slide 2: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 3: Cynata Therapeutics Overview
Cynata Therapeutics Overview • Australian Securities Exchange (ASX) listed biotech company developing a novel For personal use only therapeutic stem cell (MSC) technology: CymerusTM • Technology from University of Wisconsin - Madison: “the home of stem cells” • World-first Phase I clinical trial com
Slide 4: Cynata Key Facts
Cynata Key Facts Dr Paul Wotton – Chairman Cynata Therapeutics is an Australian clinical-stage • Former CEO of Ocata Therapeutics (NASDAQ: OCAT) managing it through a take- biotechnology company developing disruptive For personal use only over by Astellas Pharma, in a US$379 million transaction. reg
Slide 5: Our Story
Our Story For personal use only CymerusTM MSC Cymerus platform Positive pre-clinical License option Approval for Phase I platform technology successfully validated research in Graft vs. agreement with apceth clinical trials in the UK developed at Wisconsin as a GMP Host Disease, Asthma, and Australi
Slide 6: The Market
The Market For personal use only “ Global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $53.7 billion by 20211 Stem cells are the cornerstone of contemporary regenerative medicine applications2 Sources: 1. Research and Markets - Global Regenerative Medicine Marke
Slide 7: Disease Target Areas
Disease Target Areas Mesenchymal stem cells (MSCs) have broad therapeutic potential − Cynata is presently For personal use only focussing on several exciting opportunities: Graft v Host Disease Cardiovascular disease Pulmonary diseases - Brain Cancer / (GvHD) – a common (Heart Failure, Heart Pulmona
Slide 8: GvHD − A Growing Market
GvHD − A Growing Market • Graft-versus-host disease (GvHD) occurs after a bone marrow or stem cell transplant from a donor For personal use only • This is an allogeneic transplant vs. an autologous transplant (when a patient receives their own stem cells) • The transplanted cells regard the recipien
Slide 9: About Stem Cells and the Platform
About Stem Cells and the Platform For personal use only How the Cymerus MSC platform works and overcomes the inherent challenges facing MSC therapies today. Sources: 1. Research and Markets -Global Regenerative Medicine Market Analysis & Forecast 28 May, 2017 www.cynata.com 9
Slide 10: Why MSCs?
Why MSCs? For personal use only What are MSCs? CD4+ T Lymphocyte CD8+ T Lymphocyte • Mesenchymal stem cells (MSCs) are adult stem cells found in bone marrow and certain ϒδ T Cell other tissues. NK Cell What do they do? HLA-G5 • They have the ability to self renew. IDO, iNOS, HO1 PGE2 TGFβ, HGF, PGE2
Slide 11: How Are MSCs Manufactured?
How Are MSCs Manufactured? First generation methods require many tissue donors and massive cell expansion (i.e., multiply) to For personal use only manufacture sufficient product. First generation methods pose a number of key challenges for the manufacture of MSC medicines…. 1 2 3 4 5 Issues with In
Slide 12: Cymerus Platform vs First Generation Process
Cymerus Platform vs First Generation Process Cynata’s Cymerus platform enables MSCs to be manufactured effectively and efficiently by eliminating the need to use multiple donors, multiple times. For personal use only MSCs are isolated Purified MSCs are First generation Cells donated Donation taken f
Slide 13: Development Progress and Validation
Development Progress and Validation For personal use only Phase I Clinical trial in GvHD: patient dosing commenced. Strategic partnership and license option agreement with FUJIFILM Corporation. Sources: 1. Research and Markets -Global Regenerative Medicine Market Analysis & Forecast 28 May, 2017 www
Slide 14: Development Progress
Development Progress Pre-Clinical Phase 1 Phase 2 Phase 3 Evidence For personal use only Pre-clinical research with University of University of Patient Massachusetts shown Cymerus™ MSCs to be Massachusetts GvHD dosing highly effective in GvHD: CYP-001 treatment commenced substantially prolonged surv
Slide 15: Next Steps with Fujifilm
Next Steps with Fujifilm For personal use only License option agreement for further development and commercialisation of Cynata’s MSCs for GvHD License option Phase 1 Exercise of Phase 2 and agreement Fujifilm option beyond • Exclusive license • Phase 1 clinical trial • Any time up to 90 • Fujifilm
Slide 16: Business Model
Business Model For personal use only External collaborations: preclinical PoC ✓ GvHD/transplantation ✓ Asthma/respiratory disease development of potential products for ✓ Heart Attack Early Revenue Streams target diseases ✓ Cancer/Glioblastoma Upfront Option/License payments From pharma/biotech for V
Slide 17: Validation and Outlook
Validation and Outlook • Positive results from pre-clinical trials in the treatment of GvHD, asthma, heart attack and limb For personal use only ischaemia – further pre-clinical research in cancer and Acute Respiratory Distress Syndrome (ARDS) • Approval from the UK and Australia: Phase I clinical t
Slide 18: Market Activity and Investment Summary
Market Activity and Investment Summary For personal use only Regenerative medicine and stem cell market highly active with a flurry of M&A and investment in recent years. Sources: 1. Research and Markets -Global Regenerative Medicine Market Analysis & Forecast 28 May, 2017 www.cynata.com 18
Slide 19: Market Activity
Market Activity For personal use only Cord Blood Registry Acquired by AMAG USD Ocata Therapeutics (Acquired by Astellas USD Pharmaceuticals Inc 2015 700M 2016 379M Bayer and Versant Cellular Dynamics USD Ventures launched stem USD Acquired by Fujifilm cell therapy company 225M 2015 307M BlueRock The
Slide 20: Investment Summary
Investment Summary For personal use only • Only company in the world with technology for mass-production of therapeutic MSCs of consistent quality and without reliance on multiple donors • Cynata’s Cymerus™ technology overcomes the challenges inherent in first generation production methods by indust
Slide 21: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Suite 1 ross.macdonald@cynata.com 1233 High Street Armadale +61 (0) 412 119343 Victoria 3143 www.cynata.com 28 May, 2017 www.cynata.com 21
Cynata Therapeutics — Investor Presentation (May 2017) on 6ix